Scholars Central

Conference abstractPublished 29 Sep 2022

Oncolytic viruses

Authors: Robens Molaire Saintil

Journal of Emergency and Trauma Care

Volume 7 · Issue 7 · Pages 3

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The future of cancer drugs is very promising: RNA therapies, bacteria and oncolytic viruses are between the drugs oncologists have or will have to treat their patients. About the last one, since 1950s scientists began testing interferonsensitive viruses with natural oncotropism and in 1990s, they have been modifying viruses and bacteria to develop tumor selectivity and they can reprogram viruses into oncolytic vectors by combining three types of modification: targeting, arming and shielding. Currently, oncolytic viruses are powerful new therapeutic agents in cancer therapy and include viruses found in nature and viruses modified in the laboratory to reproduce efficiently in cancer cells without harming healthy cells. One oncolytic virus, T- VEC, a genetically modified form of a herpes virus for treating melanoma has been approved by the Food and Drug Administration. Another approved oncolytic virus is Rigvir in Latvia and Georgia for melanoma, pancreatic, kidney and lung cancer. Laboratory studies conducted at the Memorial Sloan-Kettering Cancer Center suggest too triple- negative breast cancer might respond to treatment with an oncolytic agent and many other types of cancer like brain cancer can be treated with new approach. Studies are currently ongoing about the compatibility between oncolytic virotherapy, chemotherapy like paclitaxel for breast cancer checkpoint inhibitors in patients with melanoma. In general, oncolytic virus treatment has a safety profile and the side effects associated with T-VEC include chills, flu-like symptoms, injection site pain, nausea and fever. The main mechanism used by virus to kill tumors according consensus involves an important immune component to the response. In the other hand, some of the challenges of virotherapy include systemic delivery, intratumoral spread and improving anti-tumor versus anti-virus immune response and many trials are ongoing to address it and many other points of interest

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Emergency and Trauma Care.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Emergency and Trauma Care
  • SubjectAnaesthesia & Pain
  • BylineArticles whose byline prints “Robens Molaire Saintil”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels